Hikma launches Triazolam Tablets


Hikma launches Triazolam Tablets

London, 19 November 2018 – Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc., formerly known as West-Ward Pharmaceuticals Corp., has launched Triazolam Tablets, 0.125mg and 0.25mg the generic equivalent to Halcion®.

Hikma’s Triazolam tablets are indicated for the short-term treatment of insomnia (generally seven to ten days). Use for more than two or three weeks requires complete reevaluation of the patient.

Prescriptions for triazolam tablets should be written for short-term use (seven to ten days) and it should not be prescribed in quantities exceeding a one-month supply.

According to IQVIA, US sales of Triazolam Tablets were approximately $27 million in the 12 months ending September 2018.

Brian Hoffmann, President, Generics Division, said, “We are excited to launch Triazolam Tablets, improving patients’ access to this product.  This launch highlights the successful execution of our strategy to develop more differentiated products by leveraging our specialised manufacturing capabilities.”